Drugs / Moxonidine
Moxonidine
also known as
BDF-5896 · BE-5895 · Brand name = Physiotens · Cynt · Fisiotens · LY-326869 · Moxonidina · MOXONIDINE HYDROCHLORIDE · +2 more
Small molecule targets NISCH via activation
Trials 15
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 02 trials | ||||||
| Phase 0 | NCT04140721 | Aug 2021 → Dec 2025 overdue | postural orthostatic tachycardia syndrome | Vanderbilt University Medical Center | Active not recruiting | No outcome recorded |
| Phase 0 | NCT04050410 | Aug 2019 → Dec 2025 overdue | postural orthostatic tachycardia syndrome | Vanderbilt University Medical Center | Active not recruiting | No outcome recorded |
| Phase 11 trial | ||||||
| Phase 1 | NCT04329806 | Feb 2021 → Jul 2022 | abdominal obesity-metabolic syndrome | Italo Biaggioni | Terminated | No outcome recorded |
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT05312892 | May 2022 → Dec 2028 expected | hypertensive disorder, obesity disorder | Vanderbilt University Medical Center | Recruiting | No outcome recorded |
| Phase 31 trial | ||||||
| Phase 3 | NCT00160277 | Jul 2005 → ? | essential hypertension | Solvay Pharmaceuticals | Completed | No outcome recorded |
| Phase 48 trials | ||||||
| Phase 4 | NCT04023565 | Mar 2019 → Jun 2020 | hypertensive disorder, metabolic syndrome X | Sergey V. Nedogoda | Unknown | No outcome recorded |
| Phase 4 | NCT04479813 | Jul 2015 → Mar 2022 | sympathetic nervous system disorder | Royal Perth Hospital | Completed | No outcome recorded |
| Phase 4 | NCT04474899 | Jun 2015 → Feb 2024 | hypertensive disorder, obesity disorder | Royal Perth Hospital | Unknown | No outcome recorded |
| Phase 4 | NCT01567124 | May 2012 → ? | schizophrenia | Baker Heart and Diabetes Institute | Withdrawn | No outcome recorded |
| Phase 4 | NCT01360710 | Jan 2012 → Jan 2014 | abdominal obesity-metabolic syndrome, hypertensive disorder | Baker Heart and Diabetes Institute | Unknown | No outcome recorded |
| Phase 4 | NCT01094769 | Apr 2011 → Jan 2020 | diabetic kidney disease | Baker Heart and Diabetes Institute | Completed | No outcome recorded |
| Phase 4 | NCT01138423 | Aug 2010 → Feb 2012 | hypertensive disorder, metabolic syndrome X | UMC Utrecht | Completed | No outcome recorded |
| Phase 4 | NCT05147753 | Jan 2010 → Jun 2014 | hypertensive disorder, obesity disorder | Aristotle University Of Thessaloniki | Completed | No outcome recorded |
| Phase not applicable2 trials | ||||||
| — | NCT02355821 | Apr 2015 → Jun 2018 | hypertensive disorder, osteoporosis | National Research Center for Preventive Medicine | Completed | No outcome recorded |
| — | NCT00518479 | Sep 2003 → Apr 2004 | hypertensive disorder, hypertensive heart disease | University of Leeds | Completed | No outcome recorded |
| Comparator or background therapy4 trials | ||||||
| Phase 3 | NCT00244504 Comparator | Nov 2002 → Mar 2006 | heart disorder | University Hospital, Basel, Switzerland | Terminated | No outcome recorded |
| Phase 4 | NCT01791699 Comparator | Aug 2012 → Nov 2013 | atrial fibrillation | Spyridon Deftereos | Completed | No outcome recorded |
| Phase 4 | NCT01504321 Comparator | May 2012 → May 2015 | polycystic ovary syndrome | Baker Heart and Diabetes Institute | Completed | No outcome recorded |
| Phase 4 | NCT01180231 Comparator | Sep 2010 → Sep 2014 | obesity disorder | Baker Heart and Diabetes Institute | Unknown | No outcome recorded |
Evidence & citations 16 cited values
Every value below carries the sentence it was read from. 21 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Moxonidine | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04050410 ↗ |
| Known as | BDF-5896 | ChEMBL registry synonym — accepted as the source's own label CHEMBL19236 ↗ |
| Known as | BE-5895 | ChEMBL registry synonym — accepted as the source's own label CHEMBL19236 ↗ |
| Known as | Brand name = Physiotens | “Brand name = Physiotens” NCT01360710 ↗ |
| Known as | Cynt | ChEMBL registry synonym — accepted as the source's own label CHEMBL19236 ↗ |
| Known as | Fisiotens | ChEMBL registry synonym — accepted as the source's own label CHEMBL19236 ↗ |
| Known as | LY-326869 | ChEMBL registry synonym — accepted as the source's own label CHEMBL19236 ↗ |
| Known as | Moxonidina | ChEMBL registry synonym — accepted as the source's own label CHEMBL19236 ↗ |
| Known as | MOXONIDINE HYDROCHLORIDE | ChEMBL registry synonym — accepted as the source's own label CHEMBL19236 ↗ |
| Known as | Normatens | ChEMBL registry synonym — accepted as the source's own label CHEMBL19236 ↗ |
| Known as | Physiotens | ChEMBL registry synonym — accepted as the source's own label CHEMBL19236 ↗ |
| Action | Activate | “Nischarin agonist” CHEMBL19236 ↗ |
| Action | Inhibit | “the moxonidine molecule is known to reduce the AE protein activity.” NCT02355821 ↗ |
| Modality | Small molecule | — CHEMBL19236 ↗ |
| Route | Oral | “Small oral doses of moxonidine did not reduce the incidence of perioperative myocardial ischaemia” PMID 17968979 ↗ Dec 2007 |
| Target | NISCH | “Nischarin agonist” CHEMBL19236 ↗ |